{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:30Z","timestamp":1787841330507,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,18]],"date-time":"2016-06-18T00:00:00Z","timestamp":1466208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Insertion and\/or deletion mutations of the\n                      <jats:italic toggle=\"yes\">CALR<\/jats:italic>\n                      gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incidence of\n                      <jats:italic toggle=\"yes\">CALR<\/jats:italic>\n                      mutations was determined in an Irish cohort of patients with MPNs with a view to incorporate this analysis into a prospective screening program. A series of 202 patients with known or suspected ET and PMF were screened for the presence of CALR mutations. CALR mutations were detected in 58 patients. Type 1 and Type 1-like deletion mutations were the most common (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 40) followed by Type 2 and Type 2-like insertion mutations (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 17). The\n                      <jats:italic toggle=\"yes\">CALR<\/jats:italic>\n                      mutation profile in Irish ET and PMF patients appears similar to that in other European populations. Establishment of this mutational profile allows the introduction of a rational, molecular diagnostic algorithm in cases of suspected ET and PMF that will improve clinical management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2016.05.002","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T01:12:53Z","timestamp":1466730773000},"page":"112-115","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["CALR mutation profile in Irish patients with myeloproliferative neoplasms"],"prefix":"10.4103","volume":"9","author":[{"given":"Karl","family":"Haslam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eibhlin","family":"Conneally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary R.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oonagh","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derville","family":"O'Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Langabeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2016.05.002_b0005","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2016.05.002_b0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2016.05.002_b0015","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2016.05.002_b0020","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hemonc.2016.05.002_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0030","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.hemonc.2016.05.002_b0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.05.002_b0040","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.05.002_b0045","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1309\/AJCP5LA2LDDNQNNC","article-title":"Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms","volume":"144","author":"Mehrotra","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0050","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/leu.2015.207","article-title":"Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN","volume":"30","author":"Jeromin","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2016.05.002_b0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/ijlh.12447","article-title":"The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms","volume":"38","author":"Grinsztejn","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.hemonc.2014.12.002","article-title":"The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"8","author":"Labastida-Mercado","year":"2015","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.hemonc.2016.05.002_b0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bcmd.2015.07.005","article-title":"CALR mutations screening in wild type JAK2(V617F) and MPL(W515K\/L) Brazilian myeloproliferative neoplasm patients","volume":"55","author":"Nunes","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.hemonc.2016.05.002_b0070","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1179\/1607845415Y.0000000018","article-title":"Calreticulin mutation profile in Indian patients with primary myelofibrosis","volume":"20","author":"Sazawal","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.hemonc.2016.05.002_b0075","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3324\/haematol.2014.109249","article-title":"Calreticulin mutations in Chinese with primary myelofibrosis","volume":"99","author":"Li","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2016.05.002_b0080","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2014.115113","article-title":"JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms","volume":"100","author":"Shirane","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2016.05.002_b0085","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hemonc.2016.05.002_b0090","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/bjh.12904","article-title":"Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation","volume":"66","author":"Haslam","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0095","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bcmd.2016.01.001","article-title":"Capricious CALR mutated clones in myeloproliferative neoplasms","volume":"57","author":"Haslam","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.hemonc.2016.05.002_b0100","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2016.05.002_b0105","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/bjh.13644","article-title":"Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis","volume":"173","author":"Guglielmelli","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0110","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Bros\u00e9us","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2016.05.002_b0115","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjh.12969","article-title":"JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort","volume":"167","author":"McGaffin","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0120","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2015.1116122","article-title":"JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens","author":"Mansier","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hemonc.2016.05.002_b0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ejh.12578","article-title":"Molecular diagnostics of myeloproliferative neoplasms","volume":"95","author":"Langabeer","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2014.11.019","article-title":"Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms","volume":"39","author":"Jones","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.hemonc.2016.05.002_b0135","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/jclinpath-2012-201008","article-title":"Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm","volume":"65","author":"Langabeer","year":"2012","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0140","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.13121","article-title":"Incidence of CALR mutations in patients with splanchnic vein thrombosis","volume":"168","author":"Haslam","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2016.05.002_b0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1160\/TH15-02-0134","article-title":"Absence of CALR mutation among a cohort of 394 unselected patients with a first episode of unprovoked venous thromboembolism","volume":"115","author":"Ianotto","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hemonc.2016.05.002_b0150","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.thromres.2015.07.026","article-title":"Low incidence of CALR gene mutations in patients with cerebral venous thrombosis without overt chronic myeloproliferative neoplasm","volume":"136","author":"Verger","year":"2015","journal-title":"Thromb Res"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387616300279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387616300279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201609030-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:02Z","timestamp":1787838602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201609030-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2016.05.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}